LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
472
via markets.businessinsider.comBusiness & Companies

Vera Therapeutics reports positive final ORIGIN 3 data for atacicept in IgA nephropathy

FROM THE WIRE · MARKETS.BUSINESSINSIDER.COM

TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGF...

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive late-stage data for a biotech; relevance is company-specific rather than market-wide.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01The ORIGIN 3 final efficacy analysis of TRUTAKNA (atacicept-vymj) was positive.
  2. 02TRUTAKNA achieved statistical significance in all prespecified endpoints, including eGFR.
  3. 03The results were presented at ASN Kidney Week 2026 and published in the New England Journal of Medicine.

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.